Lexeo Therapeutics, Inc. · NASDAQ:LXEO
Paradigm Biocapital Advisors LP reported a 6.50% stake in Lexeo Therapeutics, Inc. (Schedule 13G/A)
Event Dec 31, 2025 · Filed Feb 17, 2026
Paradigm Biocapital Advisors LP reported a 6.50% stake in Lexeo Therapeutics, Inc., 4,763,198 shares, as a passive investor on Dec 31, 2025. Filed Feb 17, 2026 (Schedule 13G/A).
- Stake
- 6.50%
- Shares
- 4,763,198
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 4 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Paradigm BioCapital Advisors LP | 6.50% | 4,763,198 |
| Paradigm BioCapital Advisors GP LLC | 6.50% | 4,763,198 |
| Senai Asefaw, M.D. | 6.50% | 4,763,198 |
| Paradigm BioCapital International Fund Ltd. | 5.80% | 4,207,159 |
Source
Related
- Lexeo Therapeutics, Inc.
- Paradigm Biocapital Advisors LP
- Lexeo Therapeutics, Inc. shareholders
- Schedule 13G/A · Paradigm Biocapital Advisors LP · Aug 14, 2026
- Schedule 13G/A · Paradigm Biocapital Advisors LP · May 15, 2026
- Schedule 13G · Paradigm Biocapital Advisors LP · Nov 20, 2025
- Schedule 13G · JPMorgan Chase & Co · Oct 13, 2026
- Form 4 · Bhalla Narinder Pal · Sep 28, 2026
- Form 4 · Otero Jose Manuel · Sep 28, 2026
- Form 4 · Townsend Richard Nolan · Sep 28, 2026
- Form 4 · Tamayo Louis Edward · Aug 19, 2026